Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Shuo Meng ^a,d   Lai, Ming Nan ^b   Wei, Alan ^c   Chen, Ya Yin ^a,b   Pu, Yeong Shiau ^a   Chen, Pau Chung ^d   Wang, Jung Der ^e,f  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FENG CHIA UNIVERSITY   (Taiwan)

^c STONY BROOK UNIVERSITY   (United States)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; HERBACEOUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ARISTOLOCHIC ACID I;

ADULT; AGE; AGED; ARTICLE; BLACKFOOT DISEASE; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DRUG USE; END STAGE RENAL DISEASE; ENDEMIC DISEASE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRESCRIPTION; REIMBURSEMENT; RESIDENTIAL AREA; RISK ASSESSMENT; TAIWAN; URINARY TRACT CANCER; URINARY TRACT INFECTION; UROTHELIAL CANCER; CHEMICALLY INDUCED; COMPLICATION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RISK FACTOR; UROLOGIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARISTOLOCHIC ACIDS; COHORT STUDIES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN; UROLOGIC NEOPLASMS;

EID: 84929507677     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105218     Document Type: Article

References (45)

1. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, et al. (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391. (Pubitemid 23048140)
2. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL (1994) Identification of aristolochic acid in Chinese herbs. Lancet 343: 174. (Pubitemid 24028653)
3. Cosyns JP (2003) Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug safety : an international journal of medical toxicology and drug experience 26: 33-48.
4. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686-1692. (Pubitemid 30354515)
5. Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C (1999) Urothelial lesions in Chinese-herb nephropathy. American journal of kidney diseases : the official journal of the National Kidney Foundation 33: 1011-1017.
6. Arlt VM, Stiborova M, Schmeiser HH (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17: 265-277. (Pubitemid 34814645)
7. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102: 179-186.
8. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2009) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102: 179-186.
9. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS (1975) Increased incidence of malignancy during chronic renal failure. Lancet 1: 883-886.
10. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM (1989) Neoplasms in dialysis patients: a population-based study. American journal of kidney diseases : the official journal of the National Kidney Foundation 14: 119-123.
11. Kjellstrand CM (1979) Are malignancies increased in uremia? Nephron 23: 159-161.
12. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, et al. (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354: 93-99. (Pubitemid 29313142)
13. Chuang CH, Lee CT, Tsai TL, Chen JB, Hsu KT, et al. (2002) Urological malignancy in chronic dialysis patients. Acta Nephrologica 16: 19-24.
14. Chang CH, Yang CM, Yang AH (2007) Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 109: 1487-1492. (Pubitemid 46595682)
15. Ou JH, Pan CC, Lin JS, Tzai TS, Yang WH, et al. (2000) Transitional cell carcinoma in dialysis patients. European urology 37: 90-94. (Pubitemid 30072381)
16. Chen KS, Lai MK, Huang CC, Chu SH, Leu ML (1995) Urologic cancers in uremic patients. American journal of kidney diseases : the official journal of the National Kidney Foundation 25: 694-700.
17. Gonwa TA, Corbett WT, Schey HM, Buckalew VM, Jr. (1980) Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract. Annals of internal medicine 93: 249-252. (Pubitemid 10044706)
18. Swindle P, Falk M, Rigby R, Petrie J, Hawley C, et al. (1998) Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. British journal of urology 81: 229-233. (Pubitemid 28316457)
19. Kliem V, Thon W, Krautzig S, Kolditz M, Behrend M, et al. (1996) High mortality from urothelial carcinoma despite regular tumor screening in patients with analgesic nephropathy after renal transplantation. Transplant international : official journal of the European Society for Organ Transplantation 9: 231-235.
20. Vanherweghem LJ (1998) Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). Journal of alternative and complementary medicine 4: 9-13.
21. Chiang HS, Guo HR, Hong CL, Lin SM, Lee EF (1993) The incidence of bladder cancer in the black foot disease endemic area in Taiwan. British journal of urology 71: 274-278. (Pubitemid 23102250)
22. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, et al. (2001) Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. American journal of epidemiology 153: 411-418. (Pubitemid 32185076)
23. Wiessler M (1994) DNA adducts of pyrrolizidine alkaloids, nitroimidazoles and aristolochic acid. IARC Sci Publ: 165-177.
24. TaiwanYearbook2009 Public Health: Health Insurance.
25. NHRI-Taiwan (2003) National Health Research Database.
26. Centers-for-Disease-Control-and-Prevention (2009) International Classification of Diseases, Ninth Revision (ICD-9). Atlanta, Georgia.
27. Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331: 1675-1679. (Pubitemid 24373619)
28. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC (1999) Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81: 542-548. (Pubitemid 29458812)
29. Committee Chinese Medicine and Pharmacy DOH-T (2002) Unified Formulas.
30. Hsu Y, Tseng H, Wen K (1997) Determination of aristolochic acid in Fangchi radix. Ann Rept NLFD Taiwan ROC: 136-142 (In Chinese).
31. Tung C, Ho Y, Tsai H, Chong Y (1999) Studies on the commonly musused and adulterated Chinese crude drug species in Taiwan. Chin Med Coll J: 35-46.
32. Deng J (2002) Quality evaluation of Fang-Ji and analysis of marker constituents [dissertation]. Taiwan: Institute of Chiense Pharmaceutical Sciences, China Medical University: 75-77.
33. Chuang M, Hsu Y, Chang H, Lin J, Liao C (2002) Studies on adulteration and misusage of marketed Akebiae caulisn. Ann Rept NLFD Taiwan ROC: 104-119 (In Chinese).
34. Jong TT, Lee MR, Hsiao SS, Hsai JL, Wu TS, et al. (2003) Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal 33: 831-837.
35. Hsu Y, Lo C, Chang H, Lin J (2003) Studies on adulteration and misusage of Asari radi in the market. Ann Rept NLFD Taiwan ROC: 153-167 (In Chinese).
36. Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer research 45: 5895-5899.
37. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY (1986) A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. British journal of cancer 53: 399-405.
38. Johansson SL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Seminars in surgical oncology 13: 291-298. (Pubitemid 27332851)
39. Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, et al. (2002) Excess risk of bladder cancer in spinal cord injury: Evidence for an association between indwelling catheter use and bladder cancer. Archives of Physical Medicine and Rehabilitation 83: 346-351. (Pubitemid 34204816)
40. Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata D, et al. (2009) Urinary tract infections and reduced risk of bladder cancer in Los Angeles. British journal of cancer 100: 834-839.
41. (2008) Cancer Incidence Rate in Taiwan, 1998-2002 & 2003-2007 http://tcr.cph.ntu.edu.tw/main.php?Page=N2: Taiwan cancer registry.
42. Achenbach H, Fischer A (1997) 6-O-beta-D-glucoside of aristolochic acid IIIa and other components from the roots of Aristolochia baetica. Planta Med 63: 579. (Pubitemid 28035469)
43. TaiwanCancerRegistry (2009) Cancer incidence rate in Taiwan, 1998-2002.
44. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, et al. (2008) The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiology and drug safety 17: 609-619.
45. (2013) Adult Smoking Behavior Surveillance System,ASBS. Taipei, Taiwan.